|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:2941–34. 2019. View Article : Google Scholar
|
|
2
|
Shahrokni A and Saif MW: Metastatic
pancreatic cancer: The dilemma of quality vs. quantity of life.
JOP. 14:391–394. 2013.PubMed/NCBI
|
|
3
|
Farrell TJ, Barbot DJ and Rosato FE:
Pancreatic resection combined with intraoperative radiation therapy
for pancreatic cancer. Ann Surg. 226:66–69. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Noel M, O'Reilly EM, Wolpin BM, Ryan DP,
Bullock AJ, Britten CD, Linehan DC, Belt BA, Gamelin EC, Ganguly B,
et al: Phase 1b study of a small molecule antagonist of human
chemokine (C-C motif) receptor 2 (PF-04136309) in combination with
nab-paclitaxel/gemcitabine in first- line treatment of metastatic
pancreatic ductal adenocarcinoma. Invest New Drugs. 38:800–811.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hood JL, San RS and Wickline SA: Exosomes
released by melanoma cells prepare sentinel lymph nodes for tumor
metastasis. Cancer Res. 71:3792–3801. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van der Pol E, Boing AN, Harrison P, Sturk
A and Nieuwland R: Classification, functions, and clinical
relevance of extracellular vesicles. Pharmacol Rev. 64:676–705.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taylor DD and Gercel-Taylor C:
Exosomes/microvesicles: Mediators of cancer-associated
immunosuppressive microenvironments. Semin Immunopathol.
33:441–454. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Corrado C, Raimondo S, Chiesi A, Ciccia F,
De Leo G and Alessandro R: Exosomes as intercellular signaling
organelles involved in health and disease: Basic science and
clinical applications. Int J Mol Sci. 14:5338–5366. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Min L, Shen J, Tu C, Hornicek F and Duan
Z: The roles and implications of exosomes in sarcoma. Cancer
Metastasis Rev. 35:377–390. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kalluri R: The biology and function of
exosomes in cancer. J Clin Invest. 126:1208–1215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luga V, Zhang L, Viloria-Petit AM,
Ogunjimi AA, Inanlou MR, Chiu E, Buchanan M, Hosein AN, Basik M and
Wrana JL: Exosomes mediate stromal mobilization of autocrine
Wnt-PCP signaling in breast cancer cell migration. Cell.
151:1542–1556. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Szajnik M, Czystowska M, Szczepanski MJ,
Mandapathil M and Whiteside TL: Tumor-derived microvesicles induce,
expand and up-regulate biological activities of human regulatory T
cells (Treg). PLoS One. 5:e114692010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Demory Beckler M, Higginbotham JN,
Franklin JL, Ham AJ, Halvey PJ, Imasuen IE, Whitwell C, Li M,
Liebler DC and Coffey RJ: Proteomic analysis of exosomes from
mutant KRAS colon cancer cells identifies intercellular transfer of
mutant KRAS. Mol Cell Proteomics. 12:343–355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu L, Li J, Gong Y, Wu Q, Tan S, Sun D,
Xu X, Zuo Y, Zhao Y, Wei YQ, et al: Exosomal tRNA-derived small RNA
as a promising biomarker for cancer diagnosis. Mol Cancer.
18:742019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharma R, Huang X, Brekken RA and Schroit
AJ: Detection of phosphatidylserine-positive exosomes for the
diagnosis of early-stage malignancies. Br J Cancer. 117:545–552.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ishihama Y: Proteomic LC-MS systems using
nanoscale liquid chromatography with tandem mass spectrometry. J
Chromatogr A. 1067:73–83. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vyas N and Dhawan J: Exosomes: Mobile
platforms for targeted and synergistic signaling across cell
boundaries. Cell Mol Life Sci. 74:1567–1576. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie F, Li C, Zhang X, Peng W and Wen T:
MiR-143-3p suppresses tumorigenesis in pancreatic ductal
adenocarcinoma T by targeting KRAS. Biomed Pharmacother.
119:1094242019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kamerkar S, LeBleu VS, Sugimoto H, Yang S,
Ruivo CF, Melo SA, Lee JJ and Kalluri R: Exosomes facilitate
therapeutic targeting of oncogenic KRAS in pancreatic cancer.
Nature. 546:498–503. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Riches A, Campbell E, Borger E and Powis
S: Regulation of exosome release from mammary epithelial and breast
cancer cells-a new regulatory pathway. Eur J Cancer. 50:1025–1034.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kucharzewska P, Christianson HC, Welch JE,
Svensson KJ, Fredlund E, Ringnér M, Mörgelin M, Bourseau-Guilmain
E, Bengzon J and Belting M: Exosomes reflect the hypoxic status of
glioma cells and mediate hypoxia-dependent activation of vascular
cells during tumor development. Proc Natl Acad Sci USA.
110:7312–7317. 2014. View Article : Google Scholar
|
|
25
|
Yan W, Wu X, Zhou W, Fong MY, Cao M, Liu
J, Liu X, Chen CH, Fadare O, Pizzo DP, et al: Cancer-cell-secreted
exosomal miR-105 promotes tumour growth through the MYC-dependent
metabolic reprogramming of stromal cells. Nat Cell Biol.
20:597–609. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Harada T, Yamamoto H, Kishida S, Kishida
M, Awada C, Takao T and Kikuchi A: Wnt5b-associated exosomes
promote cancer cell migration and proliferation. Cancer Sci.
108:42–52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dai W, Wang Y, Yang T, Wang J, Wu W and Gu
J: Downregulation of exosomal CLEC3B in hepatocellular carcinoma
promotes metastasis and angiogenesis via AMPK and VEGF signals.
Cell Commun Signal. 17:1132019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Brantley-Sieders DM, Zhuang G, Hicks D,
Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E,
Muraoka-Cook RS and Chen J: The receptor tyrosine kinase EphA2
promotes mammary adenocarcinoma tumorigenesis and metastatic
progression in mice by amplifying ErbB2 signaling. J Clin Invest.
118:64–78. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan YC, Srivastava S, Won BM, Kanteti R,
Arif Q, Husain AN, Li H, Vigneswaran WT, Pang KM, Kulkarni P, et
al: EPHA2 mutations with oncogenic characteristics in squamous cell
lung cancer and malignant pleural mesothelioma. Oncogenesis.
8:492019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Miao B, Ji Z, Tan L, Taylor M, Zhang J,
Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, et al: EPHA2
is a mediator of vemurafenib resistance and a novel therapeutic
target in melanoma. Cancer Discov. 5:274–287. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takasugi M, Okada R, Takahashi A, Virya
Chen D, Watanabe S and Hara E: Small extracellular vesicles
secreted from senescent cells promote cancer cell proliferation
through EphA2. Nat Communication. 8:157292016. View Article : Google Scholar
|
|
32
|
Zhuang G, Brantley-Sieders DM, Vaught D,
Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C and Chen
J: Elevation of receptor tyrosine kinase EphA2 mediates resistance
to trastuzumab therapy. Cancer Res. 70:299–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fan J, Wei Q, Koay EJ, Liu Y, Ning B,
Bernard PW, Zhang N, Han H, Katz MH, Zhao Z and Hu Y:
Chemoresistance transmission via exosome-mediated EphA2 transfer in
pancreatic cancer. Theranostics. 8:5986–5994. 2018. View Article : Google Scholar : PubMed/NCBI
|
